Leading the Way in Life Science Technologies

GEN Exclusives

More »

The Lists

More »
Jul 24, 2012

What the Top 10 Biopharma CEOs Are Making

GEN shows you who's in the money.

What the Top 10 Biopharma CEOs Are Making

These biotech leaders are the ones bringing home the most bacon. [© Mariusz Prusaczyk - Fotolia.com]

  • #5. Eli Lilly

    John C. Lechleiter, Ph.D., Chairman, President, and CEO

    2011 Compensation: $16,370,094

    2010 Compensation: $16,504,545

    % Change: -0.8%

  • #4. Amgen

    Kevin W. Sharer, Chairman and CEO

    2011 Compensation: $18,850,311

    2010 Compensation: $21,138,133

    % Change: -10.8%

  • #3. Abbott

    Miles D. White, Chairman, CEO, and Director

    2011 Compensation: $24,010,902

    2010 Compensation: $25,564,283

    % Change: -6.1%

  • #2. Pfizer

    Ian Read, Chairman and CEO

    2011 Compensation: $25,013,348

    2010 Compensation: $17,396,112

    % Change: 43.8%

  • #1. Johnson & Johnson

    William C. Weldon, Chairman/CEO

    2011 Compensation: $26,797,939

    2010 Compensation: $28,720,491

    % Change: -6.7%

  •  

    Leave a comment by clicking the “Comments” icon below. We want to hear your thoughts!



Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »